{"filing":{"accession_number":"0001193125-26-297454","cik":"0001817229","ticker":"VOR","company_name":"Vor Biopharma Inc.","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"vor-20260706.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526297454/vor-20260706.htm"},"events":[{"id":16408,"run_id":14660,"accession_number":"0001193125-26-297454","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses both a director resignation (Dr. Levin) and a director appointment (Dr. Zaccardelli). While both events are present, the principal disclosed action centers on the appointment of David Zaccardelli, Pharm.D. as a director on July 7, 2026, with detailed disclosure of his qualifications, compensation arrangements (annual cash retainer of $40,000 and equity grants), and board service terms. The appointment is material as it involves a change in board composition and compensation commitments.","company_name":"Vor Biopharma Inc.","ticker":"VOR","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14496,"accession_number":"0001193125-26-297454","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses both a director resignation (Dr. Levin) and a director appointment (Dr. Zaccardelli). While both events are present, the principal disclosed action centers on the appointment of David Zaccardelli, Pharm.D. as a director on July 7, 2026, with detailed disclosure of his qualifications, compensation arrangements (annual cash retainer of $40,000 and equity grants), and board service terms. The appointment is material as it involves a change in board composition and compensation commitments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T20:05:38.418649+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14496,"accession_number":"0001193125-26-297454","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses both a director resignation (Dr. Levin) and a director appointment (Dr. Zaccardelli). While both events are present, the principal disclosed action centers on the appointment of David Zaccardelli, Pharm.D. as a director on July 7, 2026, with detailed disclosure of his qualifications, compensation arrangements (annual cash retainer of $40,000 and equity grants), and board service terms. The appointment is material as it involves a change in board composition and compensation commitments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T20:05:38.418649+00:00","company_name":"Vor Biopharma Inc.","ticker":"VOR","filing_date":"2026-07-07"}]}